Dafinchi AI

Seres Therapeutics, Inc.

MCRB

Healthcare

1w

Financial Performance Summary

As of June 30, 2025, cash and cash equivalents stood at $45.4 million, with an expected cash runway into Q1 2026 based on current plans and obligations.
General and administrative expenses declined to $10.3 million from $13.1 million, driven by lower personnel and IT-related expenses.
Research and development expenses decreased to $12.9 million from $15.8 million year-over-year, reflecting completion of the SER-155 Phase Ib study and lower personnel and platform investment costs.
Seres Therapeutics reported a net loss from continuing operations of $19.9 million in Q2 2025, an improvement from $26.2 million in Q2 2024.
The company received a $25 million installment payment from Nestlé in July 2025.

EHAB

Healthcare

1w

Financial Performance Summary

Adjusted free cash flow year-to-date was $27.8 million with a 51.9% conversion rate, and debt was reduced by $10.5 million in the quarter.
Consolidated adjusted EBITDA was $26.9 million, up 6.7% year-over-year and 0.7% sequentially, with margin expanding 40 basis points to 10.1%.
Consolidated net revenue for Q2 2025 was $266.1 million, up 2.1% year-over-year and 2.4% sequentially.
Home health adjusted EBITDA was $39.3 million, up 2.6% sequentially but down 190 basis points in margin year-over-year due to mix shift.
Home health revenue was $205.9 million, down 2.0% year-over-year but up 2.6% sequentially, with volumes increasing 0.5% year-over-year and 2.1% sequentially.
Hospice revenue grew 19.4% year-over-year to $60.2 million, with adjusted EBITDA increasing 53.8% and margin expanding by 520 basis points to 23.3%.
Net debt to adjusted EBITDA leverage ratio improved to 4.3x from 5.1x in the prior year quarter.

Treace Medical Concepts, Inc.

TMCI

Healthcare

1w

Financial Performance Summary

Adjusted EBITDA loss improved significantly by 58% to $3.6 million from $8.7 million in the prior year quarter.
Cash and equivalents were $69.3 million at quarter end, with total liquidity of approximately $90.7 million including revolver access.
Cash usage decreased by 55% in Q2 and 78% year-to-date compared to 2024, supporting a targeted 50% reduction for full year 2025.
Gross margin slightly decreased to 79.7% from 80.2% in the prior year quarter.
Net loss improved by 18% to $17.4 million or $0.28 per share from $21.2 million or $0.34 per share in Q2 2024.
Operating expenses were reduced by 4% to $54.7 million compared to $57.1 million in Q2 2024 due to expense management initiatives.
Revenue in Q2 2025 was $47.4 million, a 7% increase over Q2 2024, driven by higher bunion procedure kit sales.

Anavex Life Sciences Corp.

AVXL

Healthcare

1w

Financial Performance Summary

Cash position was $101.2 million as of June 30, 2025, with no debt.
Cash runway is anticipated to be more than 3 years at the current adjusted cash utilization rate.
Cash utilization in operating activities was $12.5 million during the quarter.
General and administrative expenses increased to $4.5 million from $2.8 million year-over-year, driven by higher noncash compensation charges.
Net loss for the quarter was $13.2 million or $0.16 per share.
Research and development expenses decreased to $10 million from $11.8 million year-over-year.

Evolent Health, Inc.

EVH

Healthcare

1w

Financial Performance Summary

Cash used in operations was $26 million, influenced by performance reconciliations and a collection slowdown, with $24 million catch-up payments received post-quarter.
Normalized oncology trend for Q2 was approximately 10.5%, modestly below the initial forecast of 12% for the year.
Prior year claims development provided a favorable $11.7 million impact, partially offset by $4.6 million in revenue updates, netting a $7.1 million benefit.
Q2 adjusted EBITDA was $37.5 million, in the top half of the guided range, driven by strong results across Technology and Services and Performance Suite.
Q2 revenue was $444 million, $11 million below the midpoint of guidance, mainly due to lower 2024 revenue and go-live timing delays.
Unrestricted cash ended at $151 million at quarter-end.

Lantheus Holdings, Inc.

LNTH

Healthcare

1w

Financial Performance Summary

Adjusted net income was $110.6 million, down 12.8%, with adjusted EPS of $1.57, also down 12.8%.
Gross profit margin decreased by 80 basis points to 67.6%, mainly due to unfavorable pricing impacts.
Operating cash flow was $87.1 million, up $2.4 million year-over-year; free cash flow increased by $5.6 million to $79.1 million.
Operating expenses increased by 227 basis points to 27.2% of net revenue, reflecting investments in growth initiatives.
Operating profit declined 10.8% to $152.6 million.
Precision Diagnostics revenue increased 3.3% to $115.8 million, driven by DEFINITY sales up 7.5%.
Radiopharmaceutical oncology segment, primarily PYLARIFY, generated $250.6 million in sales, down 8.3%.
Second quarter 2025 consolidated net revenue was $378 million, down 4.1% year-over-year.
The company repurchased $100 million of shares during the quarter and completed the Evergreen acquisition for approximately $226 million net of cash.
U.S. volumes for PYLARIFY increased 2% year-over-year and over 4% sequentially but were below expectations.

Bio-Techne Corporation

TECH

Healthcare

1w

Financial Performance Summary

Adjusted EPS was $0.53, compared to $0.49 in the prior year; GAAP EPS was a loss of $0.11 versus a positive $0.25 last year.
Adjusted operating margin for Q4 was 32%, down 150 basis points year-over-year due to unfavorable product mix.
Diagnostics and Spatial Biology segment revenue declined 1% both reported and organic, with operating margin decreasing to 6% from 12.5%.
Fiscal 2025 organic revenue growth was 5%, driven by strength in biopharma and protein sciences.
GMP reagent portfolio grew 20% in Q4 and over 30% for the full fiscal year.
Protein Sciences segment revenue grew 6% reported and 4% organic with a 43.6% operating margin, up 60 basis points.
Q4 revenue was $317 million, up 3% organically and 4% reported year-over-year.
Wilson Wolf grew over 20% in fiscal 2025 with EBITDA margins north of 70%.

Medpace Holdings, Inc.

MEDP

Healthcare

4w

Financial Performance Summary

Cash flow from operations was $148.5 million, and net days sales outstanding was negative 65 days.
EBITDA for Q2 was $130.5 million, up 16.2% year-over-year, with a margin of 21.6%.
Ending backlog was approximately $2.9 billion, down 1.8% year-over-year.
Net income was $90.3 million, a 2.2% increase from the prior year, with diluted EPS of $3.10.
Net new business awards entering backlog increased 12.6% to $620.5 million, with a book-to-bill ratio of 1.03x.
Revenue for Q2 2025 was $603.3 million, a 14.2% year-over-year increase.
Share repurchases totaled 1.75 million shares for $518.5 million in Q2, with $826.3 million remaining under authorization.

Intuitive Surgical, Inc.

ISRG

Healthcare

3w

Financial Performance Summary

Da Vinci procedures increased 17% globally, with U.S. growth led by benign general surgery and international growth led by non-urology procedures.
GAAP net income was $658 million or $1.81 per share, up from $527 million or $1.46 per share last year.
Gross margin declined to 67.9% from 70% last year due to higher facilities costs, product mix, and tariffs.
Instrument and accessory revenue per procedure remained stable at approximately $1,800.
Pro forma operating margin was 39%, and pro forma earnings per share increased 23% to $2.19.
Second quarter revenue grew 21% to $2.44 billion, driven by strong procedure growth and capital placements.
SP procedures grew 88% year-over-year, and Ion procedures grew 52% to approximately 35,000.
System placements totaled 395, including 180 da Vinci 5 systems and 23 SP systems, with strong U.S. capital placements but macro challenges in Japan, China, and Europe.